Highlight
– Genetically conserved and mutation-intolerant HIV peptides were detected in rebound virus after analytic treatment interruption (ATI), reinforcing their expression and immunologic relevance in vivo.
– Individuals with transient viral control during ATI showed robust CD8 T-cell responses to these peptides, suggesting their potential as immunotherapeutic targets.
– The findings support the development of mRNA vaccines incorporating these peptides, with preclinical and translational research ongoing.
